Companies: 10,795·Total market cap: $144.5T
Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited

TLXNASDAQHealthcare● Active
$9.28
$-0.02(-0.22%)
Market Cap$3.1B
P/E Ratio
52W High$18.49
52W Low$6.28
Overview

Telix Pharmaceuticals Limited (TLX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · TLX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$0.12tlx eps ttm · tlx earnings per shareEarnings history
PE Ratio (TTM)75.3×tlx pe ratio ttm · tlx price to earningsPE Ratio deep dive
Revenue (TTM)$2.0Btlx revenue ttm · tlx annual revenueFull revenue history
Dividend YieldNo Dividenddoes tlx pay dividends · tlx dividend yieldDividend history
Shares Outstanding337.9Mtlx shares outstanding · tlx floatShares outstanding history
Next EarningsAug 20, 2026Est.tlx earnings date · tlx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$1.21B▲ +53.91% YoY
202320242025
telix pharmaceuticals limited revenue · tlx revenue 2025
FY 2025Net Income-$10.7M▼ 121.40% YoY
202320242025
telix pharmaceuticals limited net income · tlx profit 2025
FY 2025EPS$-0.03▼ 121.07% YoY
202320242025
tlx eps · telix pharmaceuticals limited earnings per share 2025
TTM:Revenue: $2.00BNet Income: $39.2MEPS: $0.12View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy5 analystsis tlx a buy · tlx analyst rating
Strong Buy
0
Buy
4
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$17.00Low
$9.28Current
$17.00Avg Target83.19% upside
$17.00High
tlx price target · tlx 12 month forecast

Total: 5 · Buy rate: 80.0%

The TLX analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $17.00, representing +83.19% upside from the current price of $9.28.

Stock Performance

Full History
1D+0.11%
1W+6.16%
1M-12.83%
3M+23.80%
YTD+24.30%
1Y-44.94%
5Y-38.55%

About Telix Pharmaceuticals Limited

CEOChristian Behrenbruch
IPO DateNov 14, 2024
Employees1,120
CountryAU

Telix Pharmaceuticals Limited a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare dis…

what is telix pharmaceuticals limited · tlx stock overview · telix pharmaceuticals limited company profile · who is telix pharmaceuticals limited ceo · tlx NASDAQ · telix pharmaceuticals limited headquarters · telix pharmaceuticals limited business segments

About Stock Overview & Key Data

Telix Pharmaceuticals Limited (TLX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Nov 14, 2024. As of the latest trading session, TLX stock price is $9.28, with a market capitalization of $3.1B. The stock has returned -44.94% over the past 12 months and +24.30% year-to-date.

According to 5 Wall Street analysts, the consensus rating for Telix Pharmaceuticals Limited stock is Buy, with an average 12-month price target of $17.00. In fiscal year 2025, Telix Pharmaceuticals Limited reported revenue of $1.2B and net income of -$10.7M. For detailed data — including Telix Pharmaceuticals Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Telix Pharmaceuticals Limited (TLX) stock price is $9.28. The stock is traded on NASDAQ under the ticker symbol TLX. The 52-week range is $6.28 – $18.49.

TLX stock priceTLX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice